Pfizer (NYSE:PFE) Updates FY 2025 Earnings Guidance

Pfizer (NYSE:PFE - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.000 for the period. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $62.9 billion.

Pfizer Stock Performance

NYSE PFE traded up $0.62 during midday trading on Wednesday, hitting $24.41. The company had a trading volume of 53,879,535 shares, compared to its average volume of 40,882,811. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a market cap of $138.44 billion, a price-to-earnings ratio of 17.31, a P/E/G ratio of 0.64 and a beta of 0.67. The firm has a fifty day simple moving average of $24.44 and a two-hundred day simple moving average of $25.85. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 EPS. The firm's quarterly revenue was down 7.8% on a year-over-year basis. Equities analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.05%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is 121.99%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $29.64.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Pfizer

A hedge fund recently raised its stake in Pfizer stock. Brighton Jones LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1,282.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 666,318 shares of the biopharmaceutical company's stock after acquiring an additional 618,117 shares during the period. Brighton Jones LLC's holdings in Pfizer were worth $17,677,000 at the end of the most recent reporting period. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.